Scholar Rock Holding (FRA:2QK) Total Operating Expense: €352.15 Mil (TTM As of Mar. 2026)


FRA:2QK Scholar Rock Holding Corp FRA:2QK
30 GF Score
Price €48.81
! 5 Warning Signs
View Full Analysis

What is Scholar Rock Holding Total Operating Expense?

Scholar Rock Holding FRA:2QK -0.63% 30 Total Operating Expense is €352.15 Mil as of Mar. 2026. GuruFocus rates FRA:2QK with a GF Score™ of 30/100. The stock has 5 warning signs investors should review.

Scholar Rock Holding's Total Operating Expense for the three months ended in Mar. 2026 was €88.24 Mil. Scholar Rock Holding's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €352.15 Mil.

Scholar Rock Holding Total Operating Expense Related Terms

Scholar Rock Holding Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Scholar Rock Holding's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scholar Rock Holding Total Operating Expense Chart

Scholar Rock Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 131.63 158.18 157.08 240.71 328.49

Scholar Rock Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.31 97.20 88.23 78.48 88.24
FRA:2QK
30GF Score
Scholar Rock Holding Corp FRA:2QK
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scholar Rock Holding Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €352.15 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €352.15 Mil mean?
Scholar Rock Holding (FRA:2QK) has a Total Operating Expense of €352.15 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Scholar Rock Holding and its competitors.
Is Scholar Rock Holding's Total Operating Expense too high?
Scholar Rock Holding's current Total Operating Expense is €352.15 Mil. Overall, Scholar Rock Holding has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's Total Operating Expense compare to COGT and CGON?
Scholar Rock Holding's Total Operating Expense of €352.15 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Scholar Rock Holding and its competitors. Scholar Rock Holding's current Total Operating Expense is €352.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Scholar Rock Holding (FRA:2QK) has a current Total Operating Expense of €352.15 Mil. The current Total Operating Expense is €352.15 Mil. Scholar Rock Holding's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current Total Operating Expense is €352.15 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scholar Rock Holding Business Description

Other Exchanges SRRK:USA2QK:Germany
Address 301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
30GF Score

Get the complete analysis for FRA:2QK

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€48.81
Price